A citation-based method for searching scientific literature

Thomas M Ackermann, Karuna Bhokare, Georg Höfner, Klaus T Wanner. Neuropharmacology 2019
Times Cited: 4







List of co-cited articles
35 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Simultaneous Multiple MS Binding Assays Addressing D1 and D2 Dopamine Receptors.
Marion Schuller, Georg Höfner, Klaus T Wanner. ChemMedChem 2017
10
75

Development of MS Binding Assays targeting the binding site of MB327 at the nicotinic acetylcholine receptor.
S Sichler, G Höfner, S Rappenglück, T Wein, K V Niessen, T Seeger, F Worek, H Thiermann, F F Paintner, K T Wanner. Toxicol Lett 2018
10
75

Simultaneous Multiple MS Binding Assays for the Dopamine, Norepinephrine, and Serotonin Transporters.
Patrick Neiens, Angela De Simone, Georg Höfner, Klaus T Wanner. ChemMedChem 2018
6
75


Affinity selection-mass spectrometry screening techniques for small molecule drug discovery.
D Allen Annis, Elliot Nickbarg, Xianshu Yang, Michael R Ziebell, Charles E Whitehurst. Curr Opin Chem Biol 2007
134
50

Mass spectrometry-based ligand binding assays on adenosine A1 and A2A receptors.
A Massink, M Holzheimer, A Hölscher, J Louvel, D Guo, G Spijksma, T Hankemeier, A P IJzerman. Purinergic Signal 2015
14
50

Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia.
John E Lisman, Joseph T Coyle, Robert W Green, Daniel C Javitt, Francine M Benes, Stephan Heckers, Anthony A Grace. Trends Neurosci 2008
704
50

GABAergic mechanisms in epilepsy.
D M Treiman. Epilepsia 2001
422
50

Recent developments in protein-ligand affinity mass spectrometry.
Niels Jonker, Jeroen Kool, Hubertus Irth, Wilfried M A Niessen. Anal Bioanal Chem 2011
58
50

Integration of Affinity Selection-Mass Spectrometry and Functional Cell-Based Assays to Rapidly Triage Druggable Target Space within the NF-κB Pathway.
Victoria D Kutilek, Christine L Andrews, Matthew P Richards, Zangwei Xu, Tianxiao Sun, Yiping Chen, Andrew Hashke, Nadya Smotrov, Rafael Fernandez, Elliott B Nickbarg,[...]. J Biomol Screen 2016
21
50

MS Binding Assays for D1 and D5 Dopamine Receptors.
Patrick Neiens, Georg Höfner, Klaus Theodor Wanner. ChemMedChem 2015
10
50

Pulsed ultrafiltration mass spectrometry: a new method for screening combinatorial libraries.
R B van Breemen, C R Huang, D Nikolic, C P Woodbury, Y Z Zhao, D L Venton. Anal Chem 1997
108
50



GABA and central neuropathic pain following spinal cord injury.
Young S Gwak, Claire E Hulsebosch. Neuropharmacology 2011
118
50

SpeedScreen: The "missing link" between genomics and lead discovery.
Hartmut Zehender, Francois Le Goff, Natalie Lehmann, Ireos Filipuzzi, Lorenz M Mayr. J Biomol Screen 2004
40
50

Discovery and characterization of orthosteric and allosteric muscarinic M2 acetylcholine receptor ligands by affinity selection-mass spectrometry.
Charles E Whitehurst, Naim Nazef, D Allen Annis, Yongmin Hou, Denise M Murphy, Peter Spacciapoli, Zhiping Yao, Michael R Ziebell, Cliff C Cheng, Gerald W Shipps,[...]. J Biomol Screen 2006
28
50

Affinity Selection-Mass Spectrometry Identifies a Novel Antibacterial RNA Polymerase Inhibitor.
Scott S Walker, David Degen, Elliott Nickbarg, Donna Carr, Aileen Soriano, Mihir Mandal, Ronald E Painter, Payal Sheth, Li Xiao, Xinwei Sher,[...]. ACS Chem Biol 2017
11
50


Role of GABA in anxiety and depression.
Allan V Kalueff, David J Nutt. Depress Anxiety 2007
262
50

Structure, function, and plasticity of GABA transporters.
Annalisa Scimemi. Front Cell Neurosci 2014
112
50

GABA mechanisms and sleep.
Claude Gottesmann. Neuroscience 2002
197
50

Glycine transporter inhibitors: A new avenue for managing neuropathic pain.
Mahmoud Al-Khrasani, Amir Mohammadzadeh, Mihály Balogh, Kornél Király, Szilvia Barsi, Benjamin Hajnal, László Köles, Zoltán S Zádori, Laszlo G Harsing. Brain Res Bull 2019
13
50

Relief of cancer pain by glycine transporter inhibitors.
Naoyo Motoyama, Katsuya Morita, Seiji Shiraishi, Tomoya Kitayama, Takashi Kanematsu, Yasuhito Uezono, Toshihiro Dohi. Anesth Analg 2014
13
50

A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease.
Katsuya Harada, Kazuhiro Nakato, Junko Yarimizu, Mayako Yamazaki, Masahiko Morita, Shinji Takahashi, Masaki Aota, Kyoko Saita, Hitoshi Doihara, Yuichiro Sato,[...]. Eur J Pharmacol 2012
49
50


Differential effects of spinally applied glycine transporter inhibitors on nociception in a rat model of neuropathic pain.
Henning Hermanns, Uta Muth-Selbach, Ruth Williams, Sabrina Krug, Peter Lipfert, Robert Werdehausen, Sebastian Braun, Inge Bauer. Neurosci Lett 2008
42
50

MS Binding Assays for Glycine Transporter 2 (GlyT2) Employing Org25543 as Reporter Ligand.
Thomas M Ackermann, Lars Allmendinger, Georg Höfner, Klaus T Wanner. ChemMedChem 2021
3
66

Long-term application of glycine transporter inhibitors acts antineuropathic and modulates spinal N-methyl-D-aspartate receptor subunit NR-1 expression in rats.
Franziska Barthel, Andrea Urban, Lukas Schlösser, Volker Eulenburg, Robert Werdehausen, Timo Brandenburger, Carmen Aragon, Inge Bauer, Henning Hermanns. Anesthesiology 2014
25
50

Glycine transport inhibitors for the treatment of pain.
Robert J Vandenberg, Renae M Ryan, Jane E Carland, Wendy L Imlach, Macdonald J Christie. Trends Pharmacol Sci 2014
49
50

The antinociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model.
Yasunori Haranishi, Koji Hara, Tadanori Terada, Seiya Nakamura, Takeyoshi Sata. Anesth Analg 2010
44
50

Spinal antiallodynia action of glycine transporter inhibitors in neuropathic pain models in mice.
Katsuya Morita, Naoyo Motoyama, Tomoya Kitayama, Norimitsu Morioka, Koki Kifune, Toshihiro Dohi. J Pharmacol Exp Ther 2008
96
50

Reversible inhibition of the glycine transporter GlyT2 circumvents acute toxicity while preserving efficacy in the treatment of pain.
A Mingorance-Le Meur, P Ghisdal, B Mullier, P De Ron, P Downey, C Van Der Perren, V Declercq, S Cornelis, M Famelart, J Van Asperen,[...]. Br J Pharmacol 2013
36
50

The first potent and selective inhibitors of the glycine transporter type 2.
W L Caulfield, I T Collie, R S Dickins, O Epemolu, R McGuire, D R Hill, G McVey, J R Morphy, Z Rankovic, H Sundaram. J Med Chem 2001
73
50

Principles of early drug discovery.
J P Hughes, S Rees, S B Kalindjian, K L Philpott. Br J Pharmacol 2011
738
25

Biochemical applications of mass spectrometry in pharmaceutical drug discovery.
Kieran F Geoghegan, Michele A Kelly. Mass Spectrom Rev 2005
48
25

Fluorescence- and bioluminescence-based approaches to study GPCR ligand binding.
Leigh A Stoddart, Carl W White, Kim Nguyen, Stephen J Hill, Kevin D G Pfleger. Br J Pharmacol 2016
65
25


The price of innovation: new estimates of drug development costs.
Joseph A DiMasi, Ronald W Hansen, Henry G Grabowski. J Health Econ 2003
25


Competitive binding assays made easy with a native marker and mass spectrometric quantification.
Georg Höfner, Klaus Theodor Wanner. Angew Chem Int Ed Engl 2003
27
25

Recent advances in functional assays of transcriptional enhancers.
Courtney C Babbitt, Michele Markstein, Jesse M Gray. Genomics 2015
10
25

Radioligand binding assays and their analysis.
Janet J Maguire, Rhoda E Kuc, Anthony P Davenport. Methods Mol Biol 2012
43
25




Mass spectrometry-based approaches to protein-ligand interactions.
Sonya M Schermann, Douglas A Simmons, Lars Konermann. Expert Rev Proteomics 2005
40
25


Applications of ESI-MS in drug discovery: interrogation of noncovalent complexes.
Steven A Hofstadler, Kristin A Sannes-Lowery. Nat Rev Drug Discov 2006
165
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.